GMT Capital Corp Increases Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

GMT Capital Corp lifted its stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 5.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,267,700 shares of the biopharmaceutical company's stock after buying an additional 170,200 shares during the period. Royalty Pharma makes up approximately 4.1% of GMT Capital Corp's investment portfolio, making the stock its 9th biggest position. GMT Capital Corp owned about 0.55% of Royalty Pharma worth $83,359,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Brooklyn Investment Group lifted its position in shares of Royalty Pharma by 1,006.9% during the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 876 shares during the period. Allworth Financial LP grew its stake in Royalty Pharma by 417.6% during the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 877 shares in the last quarter. Riverview Trust Co increased its holdings in Royalty Pharma by 3,953.3% in the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 1,186 shares during the period. Fifth Third Bancorp raised its position in shares of Royalty Pharma by 187.1% in the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 997 shares in the last quarter. Finally, Rakuten Securities Inc. boosted its position in shares of Royalty Pharma by 160.5% during the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 1,003 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $32.19 on Wednesday. The firm has a market capitalization of $18.56 billion, a price-to-earnings ratio of 22.20, a PEG ratio of 2.31 and a beta of 0.50. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The business's 50-day moving average price is $32.56 and its 200-day moving average price is $29.34. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $34.20.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Equities research analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 2.73%. The ex-dividend date is Friday, May 16th. Royalty Pharma's payout ratio is presently 60.69%.

Analyst Upgrades and Downgrades

RPRX has been the topic of a number of research analyst reports. TD Cowen raised Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $42.50.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.